PRESENTATION

Q2 2022 — Presentation

Q2 2022PDF · 29 pages2.1 MB
Merck
Q2 2022 Earnings
July 28, 2022

-- 1 of 29 --

Agenda
2
Strategy and
Business Update
Rob Davis
President & Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 29 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will
receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

-- 3 of 29 --

Strategy &
Business Update
Rob Davis
President & Chief Executive Officer

-- 4 of 29 --

Delivered on our key strategic priorities in Q2
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 29 --

Exceptional 2Q sales and earnings growth 1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations
and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have
been recast to include $4.2 billion of incremental R&D expenses, which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D
expense, which reduced EPS by $0.65.
$41.5B
+6%
$48.7B
+17%
GUIDANCE
RANGE
$57.5B-$58.5B
$14.6B
+28%
Ex-LAGEVRIO, +18%
Worldwide Sales
$1.87
+>100%
Non-GAAP EPS

-- 6 of 29 --

Advancing and providing transparency to our deep pipeline
7
Pneumococcal 	Oncology
• 	Hosted an investor event at ASCO to highlight
broad oncology portfolio and pipeline
• 	Reiterated expectation for strong growth
trajectory
• 	Made significant progress in our population-
specific approach to pneumococcal vaccines
with VAXNEUVANCE and V116
• 	Received U.S. approval and provisional
ACIP recommendation for
VAXNEUVANCE in pediatrics
• 	Presented data for V116 in adults and
initiated Phase 3 clinical trials

-- 7 of 29 --

Well positioned to deliver value to patients and shareholders
8
• 	Achieving record levels of
production in manufacturing
• 	Delivering strong revenue growth
• 	Advancing our pipeline
• 	Providing increased transparency
Significant progress
over the past year
in advancing
Merck’s position
as a global
biopharmaceutical
leader

-- 8 of 29 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 29 --

Strong Q2 sales growth across Human Health and Animal Health
10
Merck
WORLDWIDE SALES1,2,3
$14.6B+ 28% growth
+18% ex-LAGEVRIO 4
+20% ex-exchange, ex-LAGEVRIO 5
$12.8B
+28% growth
+16% ex-LAGEVRIO4
+21% ex-exchange, ex-LAGEVRIO5
Human Health 3
$1.5B
0% growth
+5% ex-exchange
Animal Health
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. In 2Q 2021 human health had ~$400M of negative
pandemic impact 4. Excludes LAGEVRIO sales of $1.2 billion in the quarter 5. Excludes LAGEVRIO sales of $1.2 billion in the quarter and foreign exchange

-- 10 of 29 --

Oncology: KEYTRUDA is having profound impact on patients
11	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $5.3B increased 30%
year-over-year, driven by robust global
demand and expansion into new indications
– In the U.S., sales of $3.2B driven by momentum in
metastatic indications as well as increased uptake
in earlier-stage cancer launches
– Ex-U.S., 22% growth was driven by global uptake
in NSCLC as well as HNSCC and advanced RCC
• KEYTRUDA is continuing to expand into
earlier-stage cancers
– 6 approved indications
– Strong uptake in certain types of TNBC, RCC and
melanoma in the U.S.
– Encouraging initial trends in treating certain types
of TNBC and RCC in key European markets
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%

-- 11 of 29 --

Oncology: Additional indications benefiting growth of key products
• Lynparza sales increased 17%, with growth
driven by adjuvant treatment of certain
patients with high-risk early-stage breast
cancer following U.S. OlympiA approval
– Maintaining position as market-leading PARP-
inhibitor
• Lenvima sales grew 33% driven by demand
following recent launches in RCC and
endometrial cancer
• WELIREG encouraging uptake in patients with
certain VHL-associated tumors
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
12	Growth rates exclude the impact of foreign exchange.

-- 12 of 29 --

Vaccines: Excellent growth driven by GARDASIL
13
• GARDASIL sales of $1.7B increased 40% year-
over-year driven by strong demand outside
the U.S. and increased supply
– Ex-U.S., growth was driven by robust demand,
particularly in China, and increased supply
– U.S. sales decreased due to CDC purchasing
patterns
Increase/decrease in sales exclude the impact of foreign exchange.
$1.2B
+78%
$656M
-24%
$1.7B
+40%

-- 13 of 29 --

Hospital: Strong global demand across broad portfolio
14
• BRIDION sales of $426M increased 15%
primarily due to greater share among
neuromuscular blockage reversal agents and
an increase in surgical procedures
• PREVYMIS sales grew 18%, driven by
continued strong global demand
• ZERBAXA benefiting from global resupply
$387M
+67%
$224M
-18%
$426M
+15%
$93M
+41%$63M
+67%
$103M
+18%
Increase/decrease in sales exclude the impact of foreign exchange.

-- 14 of 29 --

Animal Health: Solid demand driven growth
15
• Animal Health sales increased 5% to $1.5B,
reflecting growth
– Livestock sales grew 6% reflecting higher demand
globally for ruminants and poultry products
– Companion Animal sales increased 3% due to
higher global demand for the BRAVECTO
parasiticide line of products
Growth rates exclude the impact of foreign exchange.
$1.5B
+27%
$1.1B
+3%
$1.5B
+5%

-- 15 of 29 --

Q2 2022 continuing operations non-GAAP financial results summary:
Delivered strong revenue and EPS growth
Q2 2022 	Q2 2021 	Change Change
Ex-FX
Sales 	$14.6 	$11.4 	+28% 	+31%
Non-GAAP Gross
Margin 74.7% 	76.5% 	-1.8pts 	-2.5pts
Non-GAAP Operating
Expenses $5.2 	$6.6 	-21% 	-19%
Non-GAAP Tax Rate 	13.8% 	26.7% 	-12.9pts 	N/A
Non-GAAP EPS that
excludes certain items $1.87 	$0.61 	+>100% 	+>100%
$ in billions, except EPS amounts
16
Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses
non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived
in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description
of the non-GAAP adjustments, see Table 2a attached to the press release. 2021 non-GAAP results have been recast to reflect R&D business development charges related to Pandion, VelosBio and OncoImmune
totaling $1.8bn. This reduced previously reported second-quarter 2021 non-GAAP EPS of $1.31, resulting in revised non-GAAP EPS of $0.61.

-- 16 of 29 --

Merck updated full-year 2022 guidance
1. GAAP Gross Margin Rate: ~69%. 2. GAAP Operating Expenses: $21.0 to $22.0 billion. 3. GAAP Tax Rate: ~12.0% - 13.0% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q2
2022 earnings release 5. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges
related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Prior periods have been recast to reflect this change
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $56.9B to $58.1B
+17% to +19% (+19% to +21% ex-FX)
$57.5B to $58.5B
+18% to +20% (+21% to +23% ex-FX)
• 	+13% to +14% excluding LAGEVRIO and FX
impact
• 	Includes $5.0 to $5.5 billion of LAGEVRIO
revenue
• 	Assumes ~3% negative FX impact (vs. prior ~2%
negative FX impact)
Non-GAAP
Gross Margin Rate 1 	74.0% - 74.5% 	74.0% - 74.5%
Non-GAAP
Operating Expenses2 	$20.3B to $21.3B 	$20.5B to $21.5B • 	Includes upfront payment from recently
announced collaboration with Orion
Other (Income) / Expense 	~$350M of expense 	~$500M of expense • 	Reflects higher than anticipated pension
settlement expense
Tax Rate 3 	~13.5-14.5% 	~13.5-14.5%
Shares Outstanding 	~2.53B 	~2.54B
GAAP EPS 	$5.90 to $6.02 	$5.89 to $5.99
Non-GAAP EPS 4,5 	$7.24 to $7.36 	$7.25 to $7.35 • 	Assumes ~3% negative FX impact (vs. prior ~2%
negative FX impact)
17

-- 17 of 29 --

Key modeling considerations
18
Animal Health	Other Revenue 	LAGEVRIO
• 	Pandemic
unfavorably impacted
1H 2021 sales by
~$1.0B, providing a
tailwind to 1H 2022
growth
• 	Expect tailwind to
year-over-year
growth to lessen over
the remainder of
2022
• 	Normalization of
favorable
companion animal
industry trends
• 	Expect foreign
exchange
headwinds given
geographic mix
• 	Expect above
market growth in
2022
• 	Maintain full year
guidance of $5.0B
to $5.5B
• 	Expect 2H 2022
sales to be weighted
to 4Q
• 	Includes ongoing
supply sales to OGN
and JNJ, revenue
hedging program and
out-license receipts
• 	Expect Other
Revenue to be higher
in 2H vs 1H 2022
COVID-19 Impact 	Pneumococcal
• 	Expect continued
impact to
PNEUMOVAX23 in
the U.S. as market
shifts toward newer
pneumococcal
conjugate vaccines

-- 18 of 29 --

19
Continue to prioritize
investments in our
pipeline and business
to realize value
of near- and long-term
opportunities
$ Billions1
Remain committed to balanced capital allocation strategy
1. Reflects Q2 spend

-- 19 of 29 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 29 --

Driving value for patients and shareholders by progressing our pipeline
21
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the US:
• 	Received FDA approval and ACIP unanimously
voted to provisionally recommend
VAXNEUVANCE as an option for the prevention
of invasive pneumococcal disease in infants and
children
• 	FDA accepted for review a new sBLA seeking
approval for KEYTRUDA in KN-091 for the
adjuvant treatment of patients with stage IB (>4
centimeters), II or IIIA NSCLC
• 	In the EU:
• 	Received 4 EMA approvals for KEYTRUDA: in
cervical cancer based on KN-826; in MSI-H or
dMMr tumors in five different cancer types based
on KN-164 and KN-158; and as adjuvant
treatment for patients 12 years and older with
completely resected stage IIB or IIC melanoma
based on KN-7162
• 	Received positive CHMP opinion for Lynparza in
adjuvant breast cancer based on OlympiA
• 	In China:
o Received approval for Verquvo 1 in certain
patients with chronic heart failure and reduced
ejection fraction
• 	Presented data across broad oncology
portfolio at ASCO, including for KEYTRUDA
(KN-716, KN-522, KN-826) as well as Phase
1/2 data for favezelimab (anti-LAG-3) in
classical Hodgkin lymphoma
• 	Presented positive results at ISPPD from
the Phase 1/2 study, evaluating the safety,
tolerability and immunogenicity of V116;
initiated Phase 3 clinical trials
• 	Positive readout for KEYTRUDA + Padcev
(KN-869 or EV-103) in first line urothelial
cancer in patients ineligible to receive
cisplatin-based chemotherapy3
1 Partnered with Bayer 2 Approved as monotherapy for the treatment of certain adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors for five types of
cancer: unresectable or metastatic colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer 3In collaboration with Seagen and Astellas

-- 21 of 29 --

22
Pediatric
V116 (PCV21)
VAXNEUVANCE Pediatric (PCV15)
Adult
Investigational candidate specifically targeting
adult disease and covering serotypes that
account for 85% of all invasive pneumococcal
disease in US adults ages ≥651
Investigational candidate specifically
targeting pediatric disease
Expanding coverage while maintaining
protection against historically invasive
disease-causing serotypes in children
Recommended for use in sequence with
PNEUMOVAX 23
Enrolled first patient in Phase 3 trial
(STRIDE-3)
Advancing population-specific pneumococcal vaccine
development program
Approved 2021
Approved 2022 	Phase 1 in progress
1 Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs).
VAXNEUVANCE Adult (PCV15)
V117

-- 22 of 29 --

Continuing to build on momentum in oncology
23
Earlier-stage
• 	Broadest IO clinical development program
• 	KN-091 for adjuvant treatment of certain
patients with stage IB to IIIA NSCLC1
following complete surgical resection under
FDA review
• 	Expanded analyses and data on new
endpoints and key subgroups presented at
ASCO
‒ 	KN-716: adjuvant therapy for certain
patients with stage IIB and IIC melanoma
‒ 	KN-522: neoadjuvant / adjuvant high risk
early stage TNBC
‒ 	KN-564: adjuvant treatment for RCC at
intermediate-high or high risk of
recurrence post nephrectomy
Global highlights
• 	Four EMA approvals for KEYTRUDA
‒ 	KN-716: adjuvant therapy for patients
12 years and older with completely
resected stage IIB and IIC melanoma
‒ 	KN-522: neoadjuvant / adjuvant high
risk early stage TNBC
‒ 	KN-164 and KN-158: MSIH and dMMR
in 5 different cancer types1
‒ 	KN-826: certain types of persistent,
recurrent or metastatic cervical cancer
• 	Positive CHMP opinion for Lynparza for
adjuvant treatment of breast cancer based
on OlympiA2
• 	Positive topline results announced in
Phase 1b/2 study of KN-869 or EV-103 in
first line treatment of certain patients with
advanced urothelial cancer in collaboration
with Seagen and Astellas
Prostate cancer
• 	Executing on business development and
licensing strategy
‒ 	Collaboration with Orion for ODM-208 an
investigational oral, steroid synthesis
inhibitor
• 	Complements broad program including
combinations with chemotherapy and anti-
androgen therapy (KN-921, KN-641, KN-991,
PROpel)
1 Cancer types include certain unresectable or metastatic colorectal cancer; advanced or recurrent endometrial carcinoma; unresectable or metastatic gastric, small intestine or biliary cancer
2 For adjuvant treatment of patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with
neoadjuvant or adjuvant chemotherapy

-- 23 of 29 --

LAGEVRIO represents an important treatment option
against COVID-19 for high-risk, non-hospitalized patients
24
• 	Pandemic continues to evolve with regional
surges
• 	Emerging evidence of the threat of resistance
to antibody therapies with new variants
• 	LAGEVRIO is well-positioned to play a role for
appropriate high-risk patients due to its key
attributes:
– Oral treatment option
– Low propensity for drug-drug interactions
– High barrier to resistance
• 	Real-world data from Denmark, Hong Kong
and Poland support utility of LAGEVRIO

-- 24 of 29 --

Q&A
Rob Davis
President & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 25 of 29 --

Appendix
26

-- 26 of 29 --

Q2 2022 continuing operations GAAP financial results summary
27
Q2 2022 	Q2 2021 	Change Change
Ex-FX
Sales 	$14.6 	$11.4 	+28% 	+31%
Operating Expenses 	$5.3 	$6.6 	-20% 	-18%
Tax Rate 	12.0% 	29.3% 	-17.3pts 	N/A
GAAP EPS 	$1.55 	$0.48 	+>100% 	+>100%
$ in billions, except EPS amounts

-- 27 of 29 --

Capital allocation: Trailing twelve months
~$16B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Capital investments
2022 to 2026
28
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities

-- 28 of 29 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V184
Chikungunya Virus
Vaccines
Infectious diseases
MK-8189
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
General medicine
General medicine
As of August 2, 2022
V114
Pneumococcal Vaccine, adult (EU, JPN)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-6024
NASH
MK-7075 (miransertib)
Overgrowth Syndrome
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 1
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
CSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
LENVIMA (MK-7902)
HNSCC
Melanoma
CRC
Esophageal
NSCLC
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
MK-3475
(pembrolizumab
subcutaneous)
NSCLC
Islatravir (MK-8591) 1
HIV-1 prevention
MK-8591A (doravirine+islatravir) 1
HIV-1 Infection
Molnupiravir (MK-4482)
COVID-19 antiviral
KEYTRUDA (MK-3475)
Cervical (JPN)
Adjuvant RCC (JPN)
High-risk early stage TNBC (JPN)
2L HCC (US)
Adjuvant NSCLC (US, EU)
LYNPARZA (MK-7339)
Metastatic 1L Prostate (EU, JPN)
BRCA-mutated HER2-negative adjuvant Breast (JPN)
LENVIMA (MK-7902)
1L HCC (US)
MK-0616
Hypercholesterolemia
MK-2060
Cardiovascular
MK-5475
Pulmonary Arterial Hypertension
Cardiovascular
MK-5890
NSCLC
SCLC
MK-6440
(ladiratuzumab vedotin)
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
WELIREG (MK-6482)
Rare Cancers
CRC
Pancreatic
Biliary
HCC
Certain VHL tumors (EU)
LYNPARZA (MK-7339)
Advanced Solid Tumors
MK-2870
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
MK-4280
(favezelimab)
NSCLC
Hematological
Malignancies
MK-4280A
(favezelimab+pembroli
zumab)
RCC
SCLC
MK-4830
NSCLC
SCLC
RCC
CRC
Melanoma
MK-5684
Neoplasm Malignant
LENVIMA (MK-7902)
Biliary
Glioblastoma
Prostate
SCLC
Pancreas
MK-7684
(vibostolimab)
Melanoma
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Cervical
CRC
Esophageal
Breast
HNSCC
HCC
Endometrial
Prostate
Hematological
Malignancies
TUKYSA (MK-7119)
Advanced Solid Tumors
CRC
Gastric
Endometrial
NSCLC
Bladder
Biliary
Cervical
V937
Melanoma
Breast
CSCC
HNSCC
Solid Tumors
MK-0482
NSCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
Advanced Solid Tumors
HCC
CRC
SCLC
Melanoma
MK-2140 (zilovertamab
vedotin)
Breast
Gastric
Ovarian
Pancreas
NSCLC
Hematological Malignancies
Solid Tumors
Broad and innovative pipeline to solve significant unmet medical needs
29
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial Virus
V116
Pneumococcal vaccine, adult
1 On clinical hold 2U.S. NDA has not been filed
In the pipeline chart included in the Company’s Form 10-Q for the quarterly period ended June 30, 2022,
the Company inadvertently listed MK-1200 in Phase 2. MK-1200 is currently in Phase 1.
Sotatercept (MK-7962)
Pulmonary Arterial Hypertension
Cardiovascular
Infectious diseases
Molnupiravir (MK-4482) 2
COVID-19 antiviral (EU)

-- 29 of 29 --